Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
MFX Biotherapeutics (operating as mfxbio) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative targeted therapies. Their primary focus is on oncology, aiming to address unmet medical needs in cancer treatment. By leveraging advanced scientific understanding and cutting-edge technologies, mfxbio strives to improve patient outcomes in various debilitating diseases.
Serves as the central hub for research and development, clinical trial management, strategic planning, and corporate administration.
Likely equipped with modern laboratory facilities for biopharmaceutical research, cell culture suites, and collaborative office spaces designed to foster innovation. Specific architectural details are not publicly highlighted.
A dynamic and intellectually stimulating environment, characterized by a strong emphasis on scientific rigor, innovation, collaboration among multidisciplinary teams, and a shared commitment to advancing patient care through targeted therapies.
Strategically located in West Chester, Pennsylvania, part of the Greater Philadelphia life sciences corridor, providing access to a rich ecosystem of talent, research institutions, and potential collaborators. Its location supports its mission to advance cutting-edge biotherapeutics.
mfxbio's operations are primarily centered in the United States, focusing on research, development, and clinical trials. While direct global offices are not prominent, the company may engage in international collaborations for research, participate in global scientific conferences, and potentially seek regulatory approvals and partnerships in key international markets as its therapeutic candidates advance.
975 Andrew Drive
West Chester
PA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, MFX' leadership includes:
MFX has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major executive hires or exits publicly announced by mfxbio in the last 12 months. The leadership team appears stable.
Discover the tools MFX uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
mfxbio likely uses common corporate email formats. Based on the company domain mfxbiotherapeutics.com, a probable format is the first initial followed by the last name.
[first_initial][last]@mfxbiotherapeutics.com
Format
jdoe@mfxbiotherapeutics.com
Example
85%
Success rate
mfxbiotherapeutics.com • March 25, 2024
MFX Biotherapeutics announced its upcoming presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, where it will share new data on its therapeutic candidates....more
mfxbiotherapeutics.com • December 12, 2023
MFX Biotherapeutics presented promising preclinical findings for its EvaCTX™ (evofosfamide) program in combination therapy for hypoxic solid tumors at the San Antonio Breast Cancer Symposium (SABCS)....more
mfxbiotherapeutics.com • April 3, 2023
MFX Biotherapeutics received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA) to proceed with a Phase 1/2 clinical trial evaluating EvaCTX™ (evofosfamide) in combination with pembrolizumab for patients with specific types of solid tumors....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including MFX, are just a search away.